Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
16
09
2022
accepted:
09
01
2023
medline:
17
4
2023
pubmed:
19
1
2023
entrez:
18
1
2023
Statut:
ppublish
Résumé
Cutaneous lichenoid drug eruptions (LDE) are adverse drug reactions (ADR) characterized by symmetric, erythematous, violaceous papules reminiscent but rarely fully characteristic of lichen planus (LP). We aimed to analyse the literature describing cases of LDE within the last 20 years to provide additional insight into culprit drugs, typical latency to onset of the eruption, the spectrum of clinical presentations, severity and management. A literature search was conducted in MEDLINE between January 2000 and 27 January 2021. The keywords 'lichenoid drug rash' and 'lichenoid drug eruption' were used. Cases were included if LDE diagnosis was made, and culprit drugs were identified. A total of 323 cases with LDE were identified from 163 published case reports and studies. The mean patient age was 58.5 years (1 month to 92 years), and 135 patients (41.8%) were female. Checkpoint inhibitors (CKI) were the most frequently reported culprit drugs (136 cases; 42.1%), followed by tyrosine kinase inhibitors (TKI) (39 cases; 12.0%) and anti-TNF-α-monoclonal antibodies (13 cases; 4.0%). The latency between initiation of the drug and manifestation was 15.7 weeks (range: 0.1-208 weeks). After discontinuing the culprit drug, the median time to resolution was 14.2 weeks (range: 0.71-416 weeks). One hundred thirty-six patients (42.1%) were treated with topical, and 54 patients (16.7%) with systemic glucocorticoids. Overall, we conclude that, albeit rare, LDE is challenging to diagnose ADR induced by mostly CKI, TKI, and biologics. Treatment modalities resemble that of lichen planus, and the culprit drugs had to be discontinued in only 26%, which is low compared with other types of adverse drug reactions. This is probably due to the low risk of aggravation (e.g. toxic epidermal necrolysis) if the drug is continued and the benefit/risk ratio favouring the drug, as is often the case in cancer therapy.
Substances chimiques
Tumor Necrosis Factor Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
965-975Informations de copyright
© 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Sugerman PB, Satterwhite K, Bigby M. Autocytotoxic T-cell clones in lichen planus. Br J Dermatol. 2000;142(3):449-56. https://doi.org/10.1046/j.1365-2133.2000.03355.x
Eyerich K, Eyerich S. Immune response patterns in non-communicable inflammatory skin diseases. J Eur Acad Dermatol Venereol. 2018;32(5):692-703. https://doi.org/10.1111/jdv.14673
Shao S, Tsoi LC, Sarkar MK, Xing X, Xue K, Uppala R, et al. IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Sci Transl Med. 2019;11(511):eaav7561. https://doi.org/10.1126/scitranslmed.aav7561
Pietschke K, Holstein J, Meier K, Schäfer I, Müller-Hermelink E, Gonzalez-Menendez I, et al. The inflammation in cutaneous lichen planus is dominated by IFN-ϒ and IL-21-a basis for therapeutic JAK1 inhibition. Exp Dermatol. 2021;30(2):262-70. https://doi.org/10.1111/exd.14226
Meller S, Gilliet M, Homey B. Chemokines in the pathogenesis of lichenoid tissue reactions. J Invest Dermatol. 2009;129(2):315-9. https://doi.org/10.1038/jid.2008.251
Yawalkar N, Pichler WJ. Mechanisms of cutaneous drug reactions. J Dtsch Dermatol Ges. 2004;2(12):1013-23; quiz 1024-6. https://doi.org/10.1046/j.1439-0353.2004.04524.x
Reschke R, Mockenhaupt M, Simon JC, Ziemer M. Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions. J Dtsch Dermatol Ges. 2019;17(9):942-8. https://doi.org/10.1111/ddg.13876
Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016;152(10):1128-36.
Edwards C, Fearfield L. Nivolumab-induced lichenoid dermatitis occurring in a patient with metastatic melanoma successfully treated with alitretinoin. Clin Exp Dermatol. 2018;43(5):609-10. https://doi.org/10.1111/ced.13410
Diaz-Perez JA, Beveridge MG, Victor TA, Cibull TL. Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer. J Cutan Pathol. 2018;45(6):434-8. https://doi.org/10.1111/cup.13133
Matsumoto Y, Kadono T, Matsuoka M, Kawakami T, Furuya N, Doi M, et al. Disseminated erythema with intense and selective inflammation of sweat gland and lichenoid drug eruption during nivolumab therapy. J Dermatol. 2018;45(2):e33-4. https://doi.org/10.1111/1346-8138.14091
Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Milton DR, Lee CH, et al. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. J Cutan Pathol. 2019;46(9):627-36. https://doi.org/10.1111/cup.13454
Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features. Am J Dermatopathol. 2017;39(2):121-9. https://doi.org/10.1097/DAD.0000000000000688
Varma A, Friedlander P, De Moll EH, Desman G, Levitt J. Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexate. Dermatol Online J. 2020;26:13030/qt6348767t.
Martínez-Doménech Á, García-Legaz Martínez M, Magdaleno-Tapial J, Valenzuela-Oñate C, Pérez-Pastor G, Pérez-Ferriols A. Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy. Dermatol Online J. 2019;25(9):13030/qt8sm0j7t7.
Fixsen E, Patel J, Selim MA, Kheterpal M. Resolution of Pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine. Oncologist. 2019;24(3):e103-5.
Joseph RW, Cappel M, Goedjen B, Gordon M, Kirsch B, Gilstrap C, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015;3:18-22.
Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol. 2018;154(9):1057-61. https://doi.org/10.1001/jamadermatol.2018.1912
Chou S, Zhao C, Hwang SJE, Fernandez-Penas P. PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-report of 4 cases. J Cutan Pathol. 2017;44(10):851-6. https://doi.org/10.1111/cup.13013
Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;3:455-61.e1.
Davis MJ, Wilken R, Fung MA, Tartar DM. Debilitating erosive lichenoid interface dermatitis from checkpoint inhibitor therapy. Dermatol Online J. 2018;24(4):13030/qt3vq6b04v.
Schaberg KB, Novoa RA, Wakelee HA, Kim J, Cheung C, Srinivas S, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol. 2016;43(4):339-46. https://doi.org/10.1111/cup.12666
Shen J, Chang J, Mendenhall M, Cherry G, Goldman JW, Kulkarni RP. Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. Ther Adv Med Oncol. 2018;10:1758834017751634.
Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, et al. Lichenoid dermatitis from immune checkpoint inhibitor therapy: an immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol. 2019;46(11):872-7. https://doi.org/10.1111/cup.13536
Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019;80(4):990-7.
Randhawa M, Archer C, Gaughran G, Miller A, Morey A, Dua D, et al. Combined immune therapy grade IV dermatitis in metastatic melanoma. Asia Pac J Clin Oncol. 2019;15(4):262-5. https://doi.org/10.1111/ajco.13136
Rovers JFJ, Bovenschen HJ. Dermatological side effects rarely interfere with the continuation of checkpoint inhibitor immunotherapy for cancer. Int J Dermatol. 2020;59(12):1485-90. https://doi.org/10.1111/ijd.15163
Guggina LM, Yanes DA, Choi JN. Inverse lichenoid drug eruption associated with nivolumab. JAAD Case Rep. 2017;3(1):7-9. https://doi.org/10.1016/j.jdcr.2016.11.002
Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12-25. https://doi.org/10.1016/j.ejca.2016.02.010
Coscarart A, Martel J, Lee MP, Wang AR. Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus. J Cutan Pathol. 2020;47(3):275-9. https://doi.org/10.1111/cup.13587
Wu J, Vender R, Jambrosic J. Drug-induced lichenoid dermatitis with histopathologic features of mycosis fungoides in a patient with psoriasis. J Cutan Med Surg. 2010;14(6):307-9. https://doi.org/10.2310/7750.2010.09073
Luo JR, Xiang XJ, Xiong JP. Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor. Int J Clin Pharmacol Ther. 2016;54(9):719-22.
Saini K, Sutaria A, Shah B, Brahmbhatt V, Parmar K. Cutaneous adverse drug reactions to targeted chemotherapeutic drugs: a clinico-epidemiological study. Indian J Dermatol. 2019;64(6):471-5.
Penn EH, Chung HJ, Keller M. Imatinib mesylate-induced lichenoid drug eruption. Cutis. 2017;99(3):189-92.
Kagimoto Y, Mizuashi M, Kikuchi K, Aiba S. Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate. Int J Dermatol. 2014;53(3):e161-2. https://doi.org/10.1111/ijd.12174
Bhatia R, Gautam SK, Cannon A, Thompson C, Hall BR, Aithal A, et al. Cancer-associated mucins: role in immune modulation and metastasis. Cancer Metastasis Rev. 2019;38(1-2):223-36. https://doi.org/10.1007/s10555-018-09775-0
De D, Malhotra P, Saikia UN. Imatinib mesylate-induced severe lichenoid rash. Indian J Dermatol Venereol Leprol. 2014;80(1):93-5.
Patel AB, Solomon AR, Mauro MJ, Ehst BD. Unique cutaneous reaction to second- and third-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Dermatology. 2016;232(1):122-5.
Ho YH, Chen CL. Crizotinib-induced lichenoid drug eruption in a patient with lung cancer. Cutis. 2018;102(6):403-6.
O'Brien KF, Maiman RE, DeWitt CA. Clinical pathologic mismatch in a TNF-α inhibitor-associated drug reaction. J Drugs Dermatol. 2019;18(8):828-30.
Fernández-Torres R, Paradela S, Valbuena L, Fonseca E. Infliximab-induced lichen planopilaris. Ann Pharmacother. 2010;44(9):1501-3.
Gonzalez N, Patel P, Han G. A dissimilar biosimilar? Lichenoid drug eruption induced by an infliximab biosimilar. Br J Dermatol. 2018;178(4):965-8. https://doi.org/10.1111/bjd.15686
Barrientos N, García-Sánchez S, Domínguez JD. Letter: lichenoid eruption induced by etanercept. Dermatol Online J. 2012;18(7):15.
El Habr C, Meguerian Z, Sammour R. Adalimumab-induced lichenoid drug eruption. J Med Liban. 2014;62(4):238-40. https://doi.org/10.12816/0008295
Jour G, Glitza IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43(8):688-96. https://doi.org/10.1111/cup.12717
Boozalis E, Kwatra SG, Marrone KA. Bilateral lower extremity skin eruptions in an HIV-positive man receiving pembrolizumab monotherapy for non-small cell lung cancer. JAMA Oncol. 2019;5(2):261-2.
Kuraishi N, Nagai Y, Hasegawa M, Ishikawa O. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature. Acta Derm Venereol. 2010;90(1):73-6. https://doi.org/10.2340/00015555-0758
Wahiduzzaman M, Pubalan M. Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review. Dermatol Online J. 2008;14(12):14.
Chan CY, Browning J, Smith-Zagone MJ, Martinelli PT, Hsu S. Cutaneous lichenoid dermatitis associated with imatinib mesylate. Dermatol Online J. 2007;13(2):29.
Pascual JC, Matarredona J, Miralles J, Conesa V, Borras-Blasco J. Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. Int J Dermatol. 2006;45(12):1471-3. https://doi.org/10.1111/j.1365-4632.2006.03171.x
Dalmau J, Peramiquel L, Puig L, Fernández-Figueras MT, Roé E, Alomar A. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol. 2006;154(6):1213-6. https://doi.org/10.1111/j.1365-2133.2006.07276.x
Basso FG, Boer CC, Corrêa ME, Torrezan M, Cintra ML, de Magalhães MH, et al. Skin and oral lesions associated to imatinib mesylate therapy. Support Care Cancer. 2009;17(4):465-8. https://doi.org/10.1007/s00520-008-0536-8
Machaczka M, Gossart M. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia. Pol Arch Med Wewn. 2013;123(5):251-2.
Kawakami T, Kawanabe T, Soma Y. Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia. Acta Derm Venereol. 2009;89(3):325-6. https://doi.org/10.2340/00015555-0636
Prabhash K, Doval DC. Lichenoid eruption due to imatinib. Indian J Dermatol Venereol Leprol. 2005;71(4):287-8. https://doi.org/10.4103/0378-6323.16627
Ghosh SK. Generalized lichenoid drug eruption associated with imatinib mesylate therapy. Indian J Dermatol. 2013;58(5):388-92. https://doi.org/10.4103/0019-5154.117315
Garcovich S, Burlando M, Rongioletti F, Garcovich A, Parodi A, Amerio P. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect. Acta Derm Venereol. 2010;90(3):311-2. https://doi.org/10.2340/00015555-0839
Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker MJ, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol. 2009;61(1):104-11. https://doi.org/10.1016/j.jaad.2008.09.032
Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology. 2003;206(4):388-90. https://doi.org/10.1159/000069965
McPhie ML, Wang A, Molin S, Herzinger T. Lichen planopilaris induced by infliximab: a case report. SAGE Open Med Case Rep. 2020;8:2050313X20901967. https://doi.org/10.1177/2050313X20901967
Lee JH, Chung JY, Jung MY, Kim CR, Park JH, Park JH, et al. Lichenoid drug eruption after low-dose imatinib mesylate treatment. Ann Dermatol. 2013;25(4):500-2. https://doi.org/10.5021/ad.2013.25.4.500
Bovenschen HJ, Kop EN, Van De Kerkhof PC, Seyger MM. Etanercept-induced lichenoid reaction pattern in psoriasis. J Dermatolog Treat. 2006;17(6):381-3. https://doi.org/10.1080/09546630600967174
Sharma RK, Verma GK, Tegta GR, Sood S, Rattan R, Gupta M. Spectrum of cutaneous adverse drug reactions to anti-tubercular drugs and safe therapy after re-challenge - a retrospective study. Indian Dermatol Online J. 2020;11(2):177-81.
Shahul HA, Manu MK, Mohapatra AK, Mathew M. Rifampicin-induced lichenoid eruptions. BMJ Case Rep. 2014;2014:bcr2013202346. https://doi.org/10.1136/bcr-2013-202346
Ladhari C, Fathallah N, Mokni S, Sriha B, Ben SC. Lichenoid drug eruption associated with rifampicin. Presse Med. 2018;47(3):281-2.
Thakur BK, Verma S, Mishra J. Lichenoid drug reaction to isoniazid presenting as exfoliative dermatitis in a patient with acquired immunodeficiency syndrome. Int J STD AIDS. 2015;26(7):512-5.
Sharma PK, Gautam RK, Bhardwaj M, Kar HK. Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption. J Dermatol. 2001;28(12):737-41.
Kim J, Park S, Jung CM, Oh CW, Kwon JW. A case of cycloserine-induced lichenoid drug eruption supported by the lymphocyte transformation test. Allergy Asthma Immunol Res. 2017;9(3):281-4.
Cho HK, Lee SY. Prominent alopetic lesions of lichenoid drug eruption treated with topical tacrolimus. Ann Dermatol. 2014;26(1):141-3. https://doi.org/10.5021/ad.2014.26.1.141
Katare A, Arora P, Sardana K, Malhotra P. Lichenoid drug reaction due to anti-tubercular therapy presenting as erythroderma. Dermatol Ther. 2020;33(1):e13169. https://doi.org/10.1111/dth.13169
Gupta M, Gupta H, Gupta A. Tenofovir induced lichenoid drug eruption. Avicenna J Med. 2015;5(3):95-7. https://doi.org/10.4103/2231-0770.160250
Woolley IJ, Veitch AJ, Harangozo CS, Moyle M, Korman TM. Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient. AIDS. 2004;18(13):1857-8. https://doi.org/10.1097/00002030-200409030-00019
Simpson CL, McCausland D, Chu EY. Photo-distributed lichenoid eruption secondary to direct anti-viral therapy for hepatitis C. J Cutan Pathol. 2015;42(10):769-73. https://doi.org/10.1111/cup.12532
Cheong XK, Wong Z, Nor NM, Lee BR. “Black box warning” rash with entecavir - case report. BMC Gastroenterol. 2020;20(1):305.
Virath R, Balai M, Gupta LK. Blaschkoid lichenoid drug eruption due to tenofovir. Indian Dermatol Online J. 2020;11(5):826-7. https://doi.org/10.4103/idoj.IDOJ_492_19
Baumrin E, Mosam A, Dlova NC. Giant annular lichenoid drug eruption caused by efavirenz therapy. JAAD Case Rep. 2018;4(3):256-8. https://doi.org/10.1016/j.jdcr.2017.09.033
Magro CM, Crowson AN. Lichenoid and granulomatous dermatitis. Int J Dermatol. 2000;39(2):126-33. https://doi.org/10.1046/j.1365-4362.2000.00868.x
Susong J, Carrizales S. Lichenoid photosensitivity: an unusual reaction to doxycycline and an unusual response. Cutis. 2014;93(5):E1-2.
Cohen PR, Erickson CP, Calame A. Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events. Dermatol Online J. 2020;26(7):13030/qt9jh9p0xp.
Teraki Y, Shiohara T. Spontaneous tolerance to terbinafine-induced lichenoid drug eruption. Dermatology. 2004;208(1):81-2. https://doi.org/10.1159/000075054
Zheng Y, Zhang J, Chen H, Lai W, Maibach HI. Terbinafine-induced lichenoid drug eruption. Cutan Ocul Toxicol. 2017;36(1):101-3. https://doi.org/10.3109/15569527.2016.1160101
Aslan AN, Güney MC, Akçay M, Keleş T, Bozkurt E. Lichenoid type cutaneous hyperpigmentation induced by nebivolol. Turk Kardiyol Dern Ars. 2017;45(3):268-70. https://doi.org/10.5543/tkda.2016.02151
Bodmer M, Egger SS, Hohenstein E, Beltraminelli H, Krähenbühl S. Lichenoid eruption associated with the use of nebivolol. Ann Pharmacother. 2006;40(9):1688-90. https://doi.org/10.1345/aph.1H094
Fessa C, Lim P, Kossard S, Richards S, Peñas PF. Lichen planus-like drug eruptions due to β-blockers: a case report and literature review. Am J Clin Dermatol. 2012;13(6):417-21. https://doi.org/10.2165/11634590-000000000-00000
Nguyen DL, Wittich CM. Metoprolol-induced lichenoid dermatitis. J Gen Intern Med. 2011;26(11):1379-80. https://doi.org/10.1007/s11606-011-1742-5
Mullins RJ, Lones R, Dutta B. Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops. Australas J Dermatol. 2004;45(2):151-2. https://doi.org/10.1111/j.1440-0960.2004.00074.x
Forouzan P, Riahi RR, Cohen PR. Atorvastatin-induced lichenoid drug eruption: a case report and review of statin-associated cutaneous adverse events. Cureus. 2020;12(3):e7155.
Pua VS, Scolyer RA, Barnetson RS. Pravastatin-induced lichenoid drug eruption. Australas J Dermatol. 2006;47(1):57-9. https://doi.org/10.1111/j.1440-0960.2006.00225.x
Wong ITY, Huang Y, Zhou Y. Drug eruption to rosuvastatin with recurrence on simvastatin: a case report. J Cutan Med Surg. 2018;22(3):359-61. https://doi.org/10.1177/1203475418756376
Sebök B, Tóth M, Anga B, Harangi F, Schneider I. Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin). Acta Derm Venereol. 2004;84(3):229-30. https://doi.org/10.1080/00015550310006851
Vesza Z, Pires C, da Silva PM. Statin-related lichenoid dermatosis: an uncommon adverse reaction to a common treatment. Eur J Case Rep Intern Med. 2018;5(5):000844. https://doi.org/10.12890/2018_000844
Aouam K, Ali HB, Youssef M, Chaabane A, Hamdi MH, Boughattas NA, et al. Lichenoid eruption associated with hydrochlorothiazide and possible cross reactivity to furosemide. Therapie. 2009;64(5):344-7. https://doi.org/10.2515/therapie/2009050
Sin B, Miller M, Chew E. Hydrochlorothiazide induced lichen planus in the emergency department. J Pharm Pract. 2017;30(2):266-9. https://doi.org/10.1177/0897190016630879
Gencoglan G, Ceylan C, Kazandi AC. Linear lichenoid drug eruption induced by valsartan. Clin Exp Dermatol. 2009;34(7):e334-5. https://doi.org/10.1111/j.1365-2230.2009.03283.x
Ruiz Villaverde R, Blasco Melguizo J, Linares Solano J, Serrano Ortega S. Lichen planus-like eruption due to enalapril. J Eur Acad Dermatol Venereol. 2003;17(5):612-4. https://doi.org/10.1046/j.1468-3083.2003.00810.x
Johnston GA. Thiazide-induced lichenoid photosensitivity. Clin Exp Dermatol. 2002;27(8):670-2. https://doi.org/10.1046/j.1365-2230.2002.01108.x
Ruiz-Villaverde R, Galan-Gutierrez M. Lichenoid drug eruption due to eprosartan/hydrochlorothiacide. Dermatol Reports. 2011;3(2):e31. https://doi.org/10.4081/dr.2011.e31
Pfab F, Athanasiadis GI, Kollmar A, Ring J, Ollert M. Lichenoid drug eruption due to an antihypertonic drug containing irbesartan and hydrochlorothiazide. Allergy. 2006;61(6):786-7. https://doi.org/10.1111/j.1398-9995.2006.01052.x
Kubo Y, Fukumoto D, Ishigami T, Hida Y, Arase S. Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review. J Dermatol. 2010;37(9):807-11. https://doi.org/10.1111/j.1346-8138.2010.00858.x
Desai N, Alexis AF, DeLeo VA. Facial hyperpigmentation caused by diltiazem hydrochloride. Cutis. 2010;86(2):82-4.
Jaka A, López-Pestaña A, Tuneu A, Lobo C, López-Núñez M, Ormaechea N. Letter: Photodistributed reticulated hyperpigmentation related to diltiazem. Dermatol Online J. 2011;17(7):14.
Scherschun L, Lee MW, Lim HW. Diltiazem-associated photodistributed hyperpigmentation: a review of 4 cases. Arch Dermatol. 2001;137(2):179-82.
Dogra S, Kanwar AJ. Clopidogrel bisulphate-induced photosensitive lichenoid eruption: first report. Br J Dermatol. 2003;148(3):609-10. https://doi.org/10.1046/j.1365-2133.2003.05209_17.x
Ruiz Villaverde R, Blasco Melguizo J, Mendoza Guil F, Martín Sánchez MC, Naranjo SR. Generalized lichen planus-like eruption due to acetylsalicylic acid. J Eur Acad Dermatol Venereol. 2003;17(4):470-2. https://doi.org/10.1046/j.1468-3083.2003.00614_2.x
Arias-Santiago S, Aneiros-Fernandez J, Aceituno-Madera P, Burkhardt-Perez P, Naranjo SR. Hypertrophic lichenoid eruption due to furosemide. Acta Derm Venereol. 2010;90(1):78-9. https://doi.org/10.2340/00015555-0754
Romanelli M, Rhodes A. Guanfacine-induced lichenoid drug eruption in a child with autism and attention deficit hyperactivity disorder. Pediatr Dermatol. 2014;31(5):614-5. https://doi.org/10.1111/pde.12197
Cruz MJ, Duarte AF, Baudrier T, Cunha AP, Barreto F, Azevedo F. Lichenoid drug eruption induced by misoprostol. Contact Dermatitis. 2009;61(4):240-2. https://doi.org/10.1111/j.1600-0536.2009.01616.x
Majmudar V, Al-Dulaimi H, Dodd H. Lichenoid drug eruption secondary to treatment with nicorandil? Clin Exp Dermatol. 2008;33(2):193-4. https://doi.org/10.1111/j.1365-2230.2007.02646.x
Sergeant A, Milne G, Shaffrali F. Lichenoid eruption associated with orlistat. Br J Dermatol. 2006;154(5):1020-1. https://doi.org/10.1111/j.1365-2133.2006.07220.x
Bargout R, Malhotra A. A 44-year-old man with a pruritic skin rash. Cleve Clin J Med. 2001;68(11):952-3. https://doi.org/10.3949/ccjm.68.11.952
Patil T, Hanna S, Torre W. A rare case report of apixaban-induced lichenoid eruption. Ther Adv Drug Saf. 2020;11:2042098620937884. https://doi.org/10.1177/2042098620937884
Atzori L, Pinna AL, Mantovani L, Ferreli C, Pau M, Mulargia M, et al. Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department-Cagliari University (Italy). J Eur Acad Dermatol Venereol. 2012;26(11):1424-30. https://doi.org/10.1111/j.1468-3083.2011.04313.x
Akin Belli A, Mengi G, Dere Y, Dogan G. Lichenoid drug eruption induced by colchicine. Dermatol Ther. 2016;29(1):7-9. https://doi.org/10.1111/dth.12301
An I, Demir V, Akdeniz S. Lichenoid drug eruption induced by colchicine: case report. Cutan Ocul Toxicol. 2017;36(2):199-200. https://doi.org/10.1080/15569527.2016.1206556
Lai YC, Yew YW. Lichen planus and lichenoid drug eruption after vaccination. Cutis. 2017;100(6):E6-20.
Stavrianeas NG, Katoulis AC, Kanelleas A, Hatziolou E, Georgala S. Papulonodular lichenoid and pseudolymphomatous reaction at the injection site of hepatitis B virus vaccination. Dermatology. 2002;205(2):166-8. https://doi.org/10.1159/000063898
Usman A, Kimyai-Asadi A, Stiller MJ, Alam M. Lichenoid eruption following hepatitis B vaccination: first North American case report. Pediatr Dermatol. 2001;18(2):123-6. https://doi.org/10.1046/j.1525-1470.2001.018002123.x
de Golian EW, Brennan CB, Davis LS. Lichenoid drug reaction following influenza vaccination in an HIV-positive patient: a case report and literature review. J Drugs Dermatol. 2014;13(7):873-5.
Laschinger ME, Schleichert RA, Green B. Lichenoid drug eruption after human papillomavirus vaccination. Pediatr Dermatol. 2015;32(2):e48-9. https://doi.org/10.1111/pde.12516
Gehlhausen JR, Strausburg MB, Aouthmany M, Katona TM, Turner MJ. Capecitabine-induced lichenoid drug eruption: a case report. Dermatol Online J. 2017;23(2):13030/qt75n8m2zq.
Walker G, Lane N, Parekh P. Photosensitive lichenoid drug eruption to capecitabine. J Am Acad Dermatol. 2014;71(2):e52-3.
Hague JS, Ilchyshyn A. Lichenoid photosensitive eruption due to capecitabine chemotherapy for metastatic breast cancer. Clin Exp Dermatol. 2007;32(1):102-3. https://doi.org/10.1111/j.1365-2230.2006.02245.x
Shah RA, Bennett DD, Burkard ME. Photosensitive lichenoid skin reaction to capecitabine. BMC Cancer. 2017;17(1):866.
Brauer J, Votava HJ, Meehan S, Soter NA. Lichenoid drug eruption. Dermatol Online J. 2009;15(8):13.
Bong JL, Lucke TW, Douglas WS. Lichenoid drug eruption with proton pump inhibitors. BMJ. 2000;320(7230):283. https://doi.org/10.1136/bmj.320.7230.283
May C, Fleckman P, Brandling-Bennett HA, Cole B, Sidbury R. Lichenoid drug eruption with prominent nail changes due to leflunomide in a 12-year-old child. Pediatr Dermatol. 2017;34(4):e225-6. https://doi.org/10.1111/pde.13168
Rivarola de Gutierrez E, Abaca H. Photodistributed lichenoid drug eruption with rhabdomyolysis occurring during leflunomide therapy. Dermatology. 2004;208(3):232-3. https://doi.org/10.1159/000077307
Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Risk of skin reactions when using ibuprofen-based medicines. Expert Opin Drug Saf. 2005;4(5):837-48. https://doi.org/10.1517/14740338.4.5.837
Krasowska D, Schwartz RA, Lecewicz-Torun B. Generalized lichenoid drug eruption following Blaschko lines. Int J Dermatol. 2001;40(12):774-6. https://doi.org/10.1046/j.1365-4362.2001.01187-2.x
Antiga E, Melani L, Cardinali C, Giomi B, Caproni M, Francalanci S, et al. A case of lichenoid drug eruption associated with sildenafil citratus. J Dermatol. 2005;32(12):972-5. https://doi.org/10.1111/j.1346-8138.2005.tb00884.x
Goldman BD. Lichenoid drug reaction due to sildenafil. Cutis. 2000;65(5):282-3.
Büyükgebiz B, Arslan N, Oztürk Y, Soyal C, Lebe B. Drug reaction to ursodeoxycholic acid: lichenoid drug eruption in an infant using ursodeoxycholic acid for neonatal hepatitis. J Pediatr Gastroenterol Nutr. 2002;35(3):384-6. https://doi.org/10.1097/00005176-200209000-00030
Horiuchi Y. Lichenoid eruptions due to ursodeoxycholic acid administration. Gastroenterology. 2001;121(2):501-2. https://doi.org/10.1053/gast.2001.26929
Huang YL, Hong HS, Wang ZW, Kuo TT. Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis. J Am Acad Dermatol. 2003;49(2):316-9. https://doi.org/10.1067/s0190-9622(03)00748-5
King BJ, Lehman JS, Sartori Valinotti JC. Denosumab-induced cutaneous hypersensitivity reaction with distinct clinical and histopathologic findings. J Cutan Pathol. 2018;45(2):156-8. https://doi.org/10.1111/cup.13070
Bakkour W, Coulson IH. GA101 (a novel anti-CD20 monoclonal antibody)-induced lichenoid eruption. Dermatol Ther. 2012;2(1):3. https://doi.org/10.1007/s13555-012-0003-9
O'Connor R, Flynn A, Crowther S, Tobin AM, Connolly M. Drug-induced photodistributed rash. Clin Exp Dermatol. 2017;42(5):590-2. https://doi.org/10.1111/ced.13125
Fosko SW, Chu MB, Mattox AR, Richart JM, Burkemper NM, Slutsky JB. Lichenoid reaction as a potential immune response marker of intratreatment histological response during successful vismodegib treatment for a giant basal cell carcinoma. Dermatol Ther. 2015;28(6):359-62. https://doi.org/10.1111/dth.12260
Aruta F, Iovino A, Costa C, Manganelli F, Iodice R. Lichenoid rash: a new side effect of oral cladribine. Mult Scler Relat Disord. 2020;41:102023.
Abu-Shraie NA, Alfadley AA. Lichenoid drug eruption probably associated with rofecoxib. Ann Pharmacother. 2004;38(5):795-8. https://doi.org/10.1345/aph.1D438
Powell ML, Ehrlich A, Belsito DV. Lichenoid drug eruption to salsalate. J Am Acad Dermatol. 2001;45(4):616-9. https://doi.org/10.1067/mjd.2001.114593
Dequidt L, Milpied B, Chauvel A, Seneschal J, Taieb A, Darrigade AS. A case of lichenoid and pigmented drug eruption to acetazolamide confirmed by a lichenoid patch test. J Allergy Clin Immunol Pract. 2018;6(1):283-5.
Husein-Elahmed H, Aneiros-Fernandez J, Arias-Santiago S, Aneiros-Cachaza J, Naranjo-Sintes R. Lichenoid dermatosis induced by alendronate: an unusual skin drug reaction. Acta Derm Venereol. 2010;90(3):309-10. https://doi.org/10.2340/00015555-0859
Kolm I, Eggmann N, Kamarashev J, Kerl K, French LE, Hofbauer GF. Lichenoid drug eruption following intravenous application of orally formulated diamorphine, a semisynthetic heroin. Case Rep Dermatol. 2013;5(2):176-80. https://doi.org/10.1159/000353305
Wolf IH, Smolle J, Cerroni L, Kerl H. Erythroderma with lichenoid granulomatous features induced by erythropoietin. J Cutan Pathol. 2005;32(5):371-4. https://doi.org/10.1111/j.0303-6987.2005.00327.x
Mohammed F, Wally LL, Karaban JE, Reddy VB, Lertratanakul Y. Fenofibrate-induced lichenoid drug eruption: a rare culprit. Case Rep Dermatol. 2017;9(3):236-42. https://doi.org/10.1159/000484471
Bush AE, Hymes SR, Silapunt S. Lichenoid dermatitis from interferon alpha-2a in a patient with metastatic renal cell carcinoma and seronegative HCV. J Drugs Dermatol. 2017;16(7):714-6.
Boyd AS, King LE. Lichenoid drug reaction from isotretinoin therapy. Cutis. 2001;68(4):301-3.
Jones JA, Shuler MJ, Zlotoff BJ. Levonorgestrel-releasing intrauterine system causes a lichenoid drug eruption. Cutis. 2015;96(1):E13-5.
Inoue A, Sawada Y, Ohmori S, Omoto D, Haruyama S, Yoshioka M, et al. Lichenoid drug eruption caused by limaprost alfadex. Acta Derm Venereol. 2016;96(7):997-8. https://doi.org/10.2340/00015555-2435
Dolkar T, Trinidad CM, Nelson KC, Amaria RN, Nagarajan P, Torres-Cabala CA, et al. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: a detailed examination of the clinicopathologic features. J Cutan Pathol. 2018;45(7):539-44. https://doi.org/10.1111/cup.13262
Kaur S, Bhalla M, Thami GP. Subacute lichenoid eruption due to L-thyroxine overdosage. Dermatology. 2003;206(4):346-7. https://doi.org/10.1159/000069952
King B, Knopp E, Galan A, Nuovo G, Tigelaar R, McNiff J. Palifermin-associated papular eruption. Arch Dermatol. 2009;145(2):179-82. https://doi.org/10.1001/archdermatol.2008.548
Scott WR, Silberstein L, Flatley R, Ardeshna KM, Korostoff N, Dawe S. Cutaneous reaction to pegfilgrastim presenting as severe generalized skin eruption. Br J Dermatol. 2009;161(3):717-9. https://doi.org/10.1111/j.1365-2133.2009.09371.x
Leggio L, Ferrulli A, Mirijello A, Abenavoli L, di Giuda D, Funiciello S, et al. Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities. Int J Immunopathol Pharmacol. 2007;20(1):185-90. https://doi.org/10.1177/039463200702000122
Saito M, Nakamura K, Kaneko F. Lichenoid drug eruption of nails induced by propylthiouracil. J Dermatol. 2007;34(10):696-8. https://doi.org/10.1111/j.1346-8138.2007.00361.x
Natkunarajah J, Stitson RN, Harland CC. A florid rash during summer. Photodistributed lichenoid drug eruption (LDE) secondary to quinine. Clin Exp Dermatol. 2010;35(3):e83-4. https://doi.org/10.1111/j.1365-2230.2009.03538.x
Beccastrini E, Emmi G, Caproni M, Antiga E, Francalanci S, Lorenzoni A, et al. A case of lichenoid drug eruption associated with subcutaneous immunoglobulin therapy. Clin Immunol. 2011;139(2):228-30. https://doi.org/10.1016/j.clim.2010.10.009
Shalders K, Gach JE. Photodistributed lichenoid drug eruption secondary to solifenacin. Clin Exp Dermatol. 2008;33(3):340-1. https://doi.org/10.1111/j.1365-2230.2007.02630.x
Fox GN, Harrell CC, Mehregan DR. Extensive lichenoid drug eruption due to glyburide: a case report and review of the literature. Cutis. 2005;76(1):41-5.
Koh MJ, Seah PP, Tay YK, Mancer K. Lichenoid drug eruption to terazosin. Br J Dermatol. 2008;158(2):426-7. https://doi.org/10.1111/j.1365-2133.2007.08331.x
Pérez-Pérez L, Cabanillas M, Pereiro Ferreirós MM, Peteiro C, Toribio J. Photosensitive lichenoid eruption and inhaled tiotropium bromide. Dermatology. 2007;214(1):97-8. https://doi.org/10.1159/000096922
Koumaki D, Koumaki V, Katoulis A, Boumpoucheropoulos S, Evangelou G, Stefanidou M, et al. Generalized lichen planus-like eruption related to trimebutine. Eur J Case Rep Intern Med. 2020;7(12):002103. https://doi.org/10.12890/2020_002103
Chadli Z, Chaabane A, Ben Fadhl N, Fredj NB, Boughattas NA, Aouam K. Glibenclamide-induced photodistributed lichenoid eruption: an unusual association. Therapie. 2018;73(5):429-31.
Armour K, Lowe P. Complicated lichenoid drug eruption. Australas J Dermatol. 2005;46(1):21-4. https://doi.org/10.1111/j.1440-0960.2005.00131.x
Suryana K. Lichenoid reaction caused by antihistamines and corticosteroids. J Asthma Allergy. 2020;13:205-11.
Noakes R. Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiride. Australas J Dermatol. 2003;44(4):302-3. https://doi.org/10.1046/j.1440-0960.2004.00023.x
Jeong IJ, Lee HJ, Yoon MS, Kim DH. Pirfenidone-induced lichenoid drug eruption in a patient with idiopathic lung fibrosis. Ann Dermatol. 2019;31(1):103-5. https://doi.org/10.5021/ad.2019.31.1.103
Llambrich A, Lecha M. Photoinduced lichenoid reaction by thioridazine. Photodermatol Photoimmunol Photomed. 2004;20(2):108-9. https://doi.org/10.1111/j.1600-0781.2004.00087.x
Ioannides D, Vakirlis E, Kemeny L, Marinovic B, Massone C, Murphy R, et al. European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol. 2020;34(7):1403-14. https://doi.org/10.1111/jdv.16464
Schwager Z, Stern M, Cohen J, Femia A. Clinical epidemiology and treatment of lichen planus: a retrospective review of 2 tertiary care centers. J Am Acad Dermatol. 2019;81(6):1397-9. https://doi.org/10.1016/j.jaad.2019.04.027
Wagner G, Rose C, Sachse MM. Clinical variants of lichen planus. J Dtsch Dermatol Ges. 2013;11(4):309-19. https://doi.org/10.1111/ddg.12031
Le Cleach L, Chosidow O. Clinical practice. Lichen planus. N Engl J Med. 2012;366(8):723-32. https://doi.org/10.1056/NEJMcp1103641
Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol. 1993;29(2 Pt 1):249-55. https://doi.org/10.1016/0190-9622(93)70176-t
Lehman JS, Tollefson MM, Gibson LE. Lichen planus. Int J Dermatol. 2009;48(7):682-94. https://doi.org/10.1111/j.1365-4632.2009.04062.x
Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765-70.
Bircher AJ. Uncomplicated drug-induced disseminated exanthemas. Chem Immunol Allergy. 2012;97:79-97. https://doi.org/10.1159/000335617
Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis. 2004;51(5-6):297-310. https://doi.org/10.1111/j.0105-1873.2004.00445.x
Merk HF, Vanstreels L, Megahed M. Lichenoid drug reactions. Hautarzt. 2018;69(2):116-20. https://doi.org/10.1007/s00105-017-4117-y
Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98-106. https://doi.org/10.1097/COC.0000000000000239
Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930-40. https://doi.org/10.1172/JCI91190
Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886-94. https://doi.org/10.1158/1078-0432.CCR-15-1136
Otsuka M, Sugihara S, Mori S, Hamada K, Sasaki Y, Yoshikawa S, et al. Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: a single-center retrospective study in Japan. J Dermatol. 2020;47(4):356-62. https://doi.org/10.1111/1346-8138.15246
Goldermann R, Schuppe HC, Gleichmann E, Kind P, Merk H, Rau R, et al. Adverse immune reactions to gold in rheumatoid arthritis: lack of skin reactivity. Acta Derm Venereol. 1993;73(3):220-2. https://doi.org/10.2340/0001555573220222
Lerch M, Pichler WJ. The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol. 2004;4(5):411-9. https://doi.org/10.1097/00130832-200410000-00013
Laurberg G, Geiger JM, Hjorth N, Holm P, Hou-Jensen K, Jacobsen KU, et al. Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol. 1991;24(3):434-7. https://doi.org/10.1016/0190-9622(91)70067-c
Samycia M, Lin AN. Efficacy of topical calcineurin inhibitors in lichen planus. J Cutan Med Surg. 2012;16(4):221-9. https://doi.org/10.1177/120347541201600403
Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol. 1998;134(12):1521-30. https://doi.org/10.1001/archderm.134.12.1521